Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis.

Advanced healthcare materials·2026
Same author

Ambivalent Copper: Mechanistically Distinct Immune Effects Driving Innovation in Cancer Nanomedicine.

Pharmaceutics·2026
Same author

Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models.

Cancer letters·2026
Same author

Risk factors and circumstances associated with homelessness in older adults: a scoping review of quantitative and qualitative studies.

The Gerontologist·2025
Same author

Liposomal delivery of a disulfiram metabolite drives copper-mediated tumor immunity.

International journal of pharmaceutics·2025
Same author

Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma.

Blood·2025

Related Experiment Video

Updated: Aug 27, 2025

In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish
10:26

In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish

Published on: May 8, 2020

4.7K

PEG Conjugated Zein Nanoparticles for In Vivo Use.

Courtney van Ballegooie1,2,3, Nicole Wretham1, Tanya Ren1

  • 1Experimental Therapeutics, BC Cancer Research Institute, Vancouver, BC V5Z 4E6, Canada.

Pharmaceutics
|September 23, 2022
PubMed
Summary

Researchers improved Zein nanoparticles (NPs) for drug delivery by adding polyethylene glycol (PEG). PEGylated Zein NPs show enhanced stability and low toxicity, suitable for single intravenous administration.

Keywords:
Zeinmicrofluidicsnanomedicinenanoparticlespolyethene glycolprotein-based drug delivery systems

More Related Videos

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
09:36

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo

Published on: February 5, 2019

8.8K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.3K

Related Experiment Videos

Last Updated: Aug 27, 2025

In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish
10:26

In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish

Published on: May 8, 2020

4.7K
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
09:36

Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo

Published on: February 5, 2019

8.8K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.3K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Drug Delivery

Background:

  • Zein nanoparticles (NPs) are promising for drug delivery but suffer from poor colloidal stability in physiological conditions, limiting intravenous applications.
  • Instability of Zein NPs due to pH and salt concentrations hinders their development for systemic drug delivery.

Purpose of the Study:

  • To enhance the colloidal stability of Zein NPs for intravenous drug delivery.
  • To investigate the synthesis and characterization of polyethylene glycol (PEG)-modified Zein NPs (Zein:PEG-Zein NPs).

Main Methods:

  • Zein NPs were modified with PEG using pre- or post-nanoparticle formation functionalization.
  • Synthesized Zein:PEG-Zein NPs were characterized for stability, cytotoxicity, cellular uptake, and in vivo toxicity and pharmacokinetics in mice.

Main Results:

  • Pre-functionalization of Zein with PEG yielded the most stable Zein:PEG-Zein NPs, exhibiting excellent colloidal stability for 72 hours and at 4°C for 3 months.
  • Zein:PEG-Zein NPs showed no cytotoxicity or apoptosis in vitro and demonstrated dose-, time-, and temperature-dependent cellular uptake.
  • A single intravenous dose of the most stable Zein:PEG-Zein NP formulation in mice showed no observable toxicity over 14 days, but repeat dosing led to adverse effects and faster plasma elimination.

Conclusions:

  • PEGylation via pre-functionalization significantly improves Zein NP stability for potential drug delivery applications.
  • Zein:PEG-Zein NPs are suitable for single-dose intravenous administration due to their stability and low initial toxicity.
  • Further research is needed to mitigate immune responses for safe repeat-dose intravenous administration of Zein:PEG-Zein NPs.